Angela Vasaturo, PhD; Julia Katerina Schwarze, MD
Associate Director Scientific Affairs, Ultivue; Dept of Medical Oncology, University Hospital Brussels
Combinatorial Immunotherapy Approaches for Patients with Advanced Solid Tumors
Length: 60 minutes
Relevant for
FixVUE, InSituPlex
Description In this exciting webinar co-hosted by GEN and Clinical OMICs, we explored the intratumoral administration of autologous, non-manipulated myeloid dendritic cells in combination with immune checkpoint inhibitors in patients with advanced solid tumors and in combination with the oncolytic virus talimogene laherparepvec (Imlygic®) in patients with advanced melanoma in phase I clinical trials. Additionally, we heard how on-treatment biopsies are analyzed for cellular changes with immunohistochemistry and multiplexed immunofluorescence, which could serve as a surrogate biomarker.
Meet the host
Angela Vasaturo is the Associate Director Scientific Affairs at Ultivue. Prior to joining Ultivue she was a Senior Researcher in Dr. Jerome Galon’s Laboratory of Integrative Cancer Immunology at the Cordeliers Research Centre. She has a wealth of expertise in multiplex IHC techniques, multispectral digital pathology, and tissue imaging.
Related Content
Characterizing spatial distribution of immune-cell subsets in Nonalcoholic Steatohepatitis and Primary Sclerosing Cholangitis using a novel 12-plex Ultimapper ® kit
Presented at EASL 2021
Overview of the differences between standard IHC and multiplexed immunofluoresence
Ultivue
